AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-20 and insert therefor Claims 21-35 as follow. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-20. (Canceled)

21. (New) A compound of the formula I:



I

wherein:

R^1 is selected from the group consisting of:

(1) hydrogen,

(2) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,

(3) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and

(4) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) -C_{1-6}alkyl,

(b) -O-C_{1-6}alkyl,

(c) halo,

(d) hydroxy,

(e) trifluoromethyl,

(f) -OCF_3,

(g) -CO_2R^9,

wherein R^9 is independently selected from:

(i) hydrogen,

(ii) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) benzyl, and

(iv) phenyl,

(h) $-NR^{10}R^{11}$,

wherein R^{10} and R^{11} are independently selected from:

(i) hydrogen,

(ii) $-C_{1-6}$alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) $-C_{5-6}$cycloalkyl,

(iv) benzyl,

(v) phenyl,

(vi) $-S(O)_2-C_{1-6}$alkyl,

(vii) $-S(O)_2$-benzyl, and

(viii) $-S(O)_2$-phenyl,

(i) $-CONR^{10}R^{11}$, and

(j) $-NO_2$;

(5) heterocycle, wherein heterocycle is selected from:
benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) $-C_{1-6}$alkyl,

(b) $-O-C_{1-6}$alkyl,

(c) halo,

(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) $-OCF_3$,
(h) $-CO_2R^9$,
(i) $-NR^{10}R^{11}$, and
(j) $-CONR^{10}R^{11}$;

R^2 is phenyl;

R^3 is independently selected from the group consisting of:
(1) hydrogen, and
(2) C_{1-6}alkyl;

R^4 is selected from the group consisting of:
(1) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl, phenyl or heterocycle,
(2) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) $-C_{1-6}$alkyl,
(b) $-O-C_{1-6}$alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) $-OCF_3$,
(g) $-CO_2R^9$,
(h) -CN,
(i) $-NR^{10}R^{11}$,
(j) $-CONR^{10}R^{11}$, and
(k) $-NO_2$;
(4) heterocycle, wherein heterocycle is selected from:
benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl,

pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) -C_{1-6}alkyl,
(b) -O-C_{1-6}alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) -OCF_3,
(h) -CO_2R^9,
(i) -$NR^{10}R^{11}$, and
(j) -$CONR^{10}R^{11}$;

R^5 is independently selected from the group consisting of:

(1) hydrogen,
(2) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(3) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(4) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
    (a) -C_{1-6}alkyl, which is unsubstituted or substituted with -$NR^{10}R^{11}$,
    (b) -O-C_{1-6}alkyl,
    (c) halo,

(d) hydroxy,
(e) trifluoromethyl,
(f) $-OCF_3$;
(g) $-CO_2R^9$,
(h) $-NR^{10}R^{11}$,
(i) $-C(O)NR^{10}R^{11}$, and
(j) $-NO_2$,

(5) heterocycle, wherein heterocycle is selected from: benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) $-C_{1-6}$alkyl,
(b) $-O-C_{1-6}$alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) $-OCF_3$;
(h) $-CO_2R^9$,
(i) $-NR^{10}R^{11}$, and
(j) $-CONR^{10}R^{11}$;

or a pharmaceutically acceptable salt thereof.

22. (New) The compound of Claim 21 of the formula Ia:



Ia

or a pharmaceutically acceptable salt thereof.

23. (New) The compound of Claim 22 of the formula Ib:



Ib

or a pharmaceutically acceptable salt thereof.

24. (New) The compound of Claim 23 of the formula Ic:



Ic

or a pharmaceutically acceptable salts thereof.

25. (New) The compound of Claim 21 wherein R^1 is phenyl.

26. (New) The compound of Claim 21 wherein R^3 is hydrogen.

27. (New) The compound of Claim 21 wherein R^4 is phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) -C_{1-6}alkyl,
(b) -O-C_{1-6}alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) -OCF_3;
(g) -CO_2-C_{1-6}alkyl,
(h) -CN,
(i) -NH_2,
(j) -NH-C_{1-6}alkyl,
(k) -$CONH_2$, and
(l) -CONH-C_{1-6}alkyl.

28. (New) The compound of Claim 27 wherein R^4 is phenyl, which is unsubstituted or substituted with halo or -CN.

29. (New) The compound of Claim 28 wherein R^4 is phenyl.

30. (New) The compound of Claim 21 wherein R^4 is pyridyl.

31. (New) The compound of Claim 21 wherein R^5 is hydrogen.

32. (New) A compound which is selected from the group consisting of:





































or a pharmaceutically acceptable salt thereof.

33. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 21 or a pharmaceutically acceptable salt thereof.

34. (New) A method for treating schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 21 or a pharmaceutically acceptable salt thereof.

35. (New) A method for treating anxiety in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 21 or a pharmaceutically acceptable salt thereof.